Introduction to Purple Biotech and CAPTN-3
Purple Biotech is making significant strides in the field of cancer therapy with its innovative tri-specific antibody platform known as CAPTN-3. This technology employs a conditionally activated mechanism that engages T cells and NK cells, which are crucial components of the immune system, to enhance the body’s ability to fight cancer. By generating an optimal anti-tumor immune response, Purple Biotech aims to change the landscape of cancer treatment.
Selection for Prestigious Presentation
Recently, Purple Biotech announced its selection for a poster presentation at an esteemed symposium that focuses on molecular targets and cancer therapeutics, showcasing its dedication to advancing cancer treatment. The symposium, which is a convergence of leading minds in oncology research, serves as a platform for sharing groundbreaking developments in cancer therapies.
Details of the Presentation
The poster presentation titled “CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers” will be delivered by Dr. Hadas Reuveni, the Vice President of Research and Development at Purple Biotech. This presentation will highlight how this novel platform works in activating immune responses specifically within the tumor microenvironment, making it a targeted approach to cancer treatment.
Understanding CAPTN-3
CAPTN-3 is at the forefront of cancer therapy innovation because it combines the powers of T cells and NK cells to form a robust immune synapse that offers superior anti-tumor effects. The lead compound within this platform showcases a NK cell engager that not only targets tumors but also acts like a checkpoint inhibitor, enhancing the body’s innate and adaptive immune responses against cancers.
IM1240 and Its Significance
Among the significant candidates under CAPTN-3 is IM1240, which targets 5T4—a tumor-associated antigen found in various solid tumors. This antigen is linked to advanced disease progression and poor clinical outcomes, making it a valuable target for therapeutic interventions. Its specificity only in cancer cells and not in healthy adult tissues makes it ideal for minimizing side effects while effectively attacking tumors.
Company Profile and Broader Pipeline
Purple Biotech (NASDAQ/TASE: PPBT) is not only focusing on CAPTN-3 but has a broad oncology pipeline that includes therapies such as CM24 and NT219. CM24 is designed to disrupt the tumor's ability to evade immune detection by neutralizing CEACAM1, a protein associated with tumor survival. This approach is being tested in combination with other treatments to enhance therapeutic outcomes for patients with pancreatic cancer.
Collaboration and Future Developments
Furthermore, Purple Biotech has engaged in partnerships with other industry giants to optimize clinical trials and research outcomes, advancing its position in the competitive oncology landscape. NT219, another promising candidate, works by inhibiting crucial cancer pathways and has shown encouraging results in early studies.
Revolutionizing Cancer Treatment
The preclinical platform of CAPTN-3 exemplifies a novel therapeutic strategy that could change how cancer is treated. By leveraging the body’s immune capacity, Purple Biotech is working towards therapies that potentially increase the therapeutic window for patients while specifically targeting tumors. This could result in better patient outcomes and fewer side effects, representing a significant advancement in oncology.
Company's Outreach and Contact Information
As the company continues to innovate in the field of immunology, it maintains transparency with stakeholders and the public. For those interested in more about Purple Biotech and its groundbreaking research, the company encourages reaching out through their official channels.
CONTACTS:
Company Contact:
Lior Fhima
Chief Financial Officer
IR@purple-biotech.com
Frequently Asked Questions
What is CAPTN-3?
CAPTN-3 is a tri-specific antibody platform developed by Purple Biotech to enhance immune responses against tumors.
Who is presenting the data at the symposium?
Dr. Hadas Reuveni, the VP of Research and Development at Purple Biotech, will present the poster on CAPTN-3.
What does IM1240 target?
IM1240 targets the tumor-associated antigen 5T4, which is linked to various solid tumors and poor clinical outcomes.
How is Purple Biotech collaborating with other companies?
Purple Biotech is forming collaborations with industry leaders to optimize clinical trial outcomes and enhance research efficiency.
What are the other therapies in Purple Biotech’s pipeline?
Other therapies include CM24 and NT219, which aim to disrupt tumor survival mechanisms and inhibit specific cancer pathways.
